Welcome to 4SC

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Information about Capital increase June/July 2015 (completed)

17 Nov 2015
DGAP-News: 4SC AG / Key word(s): Conference/Miscellaneous 2015-11-17 / 15:10 Announcement 4SC AG to present at two upcoming investor conferences Planegg-Martinsried,...
4SC-202: positive Phase I data ASCO 2014

Epigenetic compound 4SC-202 shows clean safety and promising signs of efficacy in haematological tumours press release, ASCO 2014 poster

Resminostat: Advancing Phase II

4SC: Phase II trial in haematological cancer indication CTCL planned... more
Yakult: Japanese Phase II trials in HCC & NSCLC ongoing ...

4SC Scientific Symposium

Learn more about the epigenetic regulation of immunogenicity, meet our speakers or have a look at the abstracts.